Evaxion A/S has achieved a significant milestone by winning the International Prix Galien Award for its AI-Immunology™ platform, recognized as the best digital health solution. This prestigious award, presented on October 30, 2026, at the American Museum of Natural History in New York City, highlights Evaxion's innovative contributions to the field of immunotherapy and artificial intelligence in healthcare.

The award is particularly notable as it is the first time a Danish company has received this honor, which is often regarded as the equivalent of the Nobel Prize in biopharmaceutical research. Evaxion's CEO, Helen Tayton-Martin, and founder and Chief AI Officer, Andreas Holm Mattsson, accepted the award, emphasizing the recognition of their pioneering work in AI-driven medical solutions.

Background

Evaxion A/S, a clinical-stage TechBio company based in Hoersholm, Denmark, specializes in developing immunotherapies powered by its proprietary AI-Immunology™ platform. The company operates under the Standard Industrial Classification (SIC) code 2836, which covers biological products (no diagnostic substances). Evaxion is publicly traded on the Nasdaq under the ticker symbol EVAX.

Recent filings indicate that Evaxion has been active in the market, with multiple submissions of Form 6-K, including the latest on October 30, 2026, detailing this award. The company has been recognized previously for its innovative approaches, winning the Prix Galien UK Award for Best Digital Health Solution in June 2026.

What the Filing Says

The SEC filing includes a press release stating, "Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution." This accolade represents an important external validation of Evaxion's approach to leveraging artificial intelligence in the development of novel immunotherapies.

Impact

This recognition may significantly impact Evaxion's positioning within the biological products industry, potentially enhancing its reputation and attracting further investment. The award not only highlights Evaxion's advancements but also raises the competitive stakes for other companies in the sector, as it underscores the increasing importance of AI in developing effective healthcare solutions.

What's Next

The filing does not say what happens next.